Testing a new drug for advanced solid tumors
Part of Cancer, Hormones & metabolism, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug called NRM-823 for people with several types of advanced cancer that have stopped responding to standard treatments. The goal is to see if the drug is safe and how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these cancer types that has spread: non-small cell lung cancer, triple-negative breast cancer, head and neck, esophageal, stomach, cervical, endometrial, or ovarian cancer.
- You should be able to perform daily activities with little or no help (ECOG 0 or 1).
- Your liver, kidneys, lungs, heart, and blood counts must be working well enough.
- You must have finished previous cancer treatments (chemotherapy, immunotherapy, radiation) at least 3 weeks or 5 half-lives before starting the study drug.
- You must not have had severe lung inflammation (pneumonitis) from past treatment that needed steroids.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called PF-08634404 in combination with standard chemotherapy for people with stomach, gastroesophageal junction, or esophagus cancer that has spread. It aims to see if adding this drug helps the treatment work better.
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests a new drug called JNJ-89862175 for people with certain advanced solid tumors, including lung adenocarcinoma, kidney cancer, ovarian cancer, and uterine cancer. The goal is to see if this treatment is safe and effective.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.